Lobular carcinoma in situ (LCIS) is not cancer, despite having “carcinoma” in its name. It’s a condition where abnormal cells accumulate inside the milk-producing glands of the breast but never break through into surrounding tissue. Rather than being a diagnosis of cancer, LCIS is a marker that your lifetime risk of developing breast cancer is roughly double the average: about 25% to 30%, compared to 13% for women overall.
The name causes understandable confusion. “Carcinoma” sounds like cancer, and “in situ” means “in place,” which sounds like early-stage cancer sitting in one spot. But the critical distinction is that LCIS cells stay contained within the breast lobules. They don’t invade nearby tissue, don’t spread, and don’t need to be treated the way cancer does. Think of it less as a tumor and more as a warning signal.
What’s Actually Happening in the Breast
Your breasts contain tiny glands called lobules that produce milk, connected by small ducts. In LCIS, cells inside these lobules start multiplying and filling the space in ways they normally wouldn’t. Under a microscope, the cells look small and uniform, loosely packed together like “marbles in a bag.” They’ve lost the molecular glue (a protein called E-cadherin) that normally holds breast cells tightly to one another.
These cells are abnormal, but they remain inside the lobule walls. That boundary is what separates LCIS from invasive lobular carcinoma, where cells break through and infiltrate surrounding breast tissue. The cellular changes in LCIS signal that the breast environment has shifted in a way that raises the odds of cancer developing later, in either breast, not just the one where LCIS was found.
Why the Name Is Misleading
The term “lobular carcinoma in situ” dates to a time when pathologists classified any abnormal-looking cell growth using cancer terminology. Medical organizations have debated renaming it for years. The World Health Organization now groups it under “non-invasive lobular neoplasia,” a broader term that better reflects its nature as a risk factor rather than a malignancy. Still, “LCIS” remains the term most doctors use in practice, which continues to alarm patients who hear it for the first time.
Classic vs. Pleomorphic LCIS
Not all LCIS behaves the same way. The most common form, classic LCIS, involves small, uniform cells with no signs of rapid division or tissue death. It rarely requires surgery beyond the biopsy that found it, and if it shows up at the edge of a surgical specimen, surgeons generally don’t go back in to remove more tissue.
Pleomorphic LCIS is a less common variant with larger, more irregular cells. It can feature areas of dead tissue in the center (necrosis) and calcifications that show up on mammograms, sometimes mimicking ductal carcinoma in situ (DCIS), which is treated more aggressively. For this reason, pleomorphic LCIS is typically managed more like DCIS: surgeons aim to remove it completely and will re-excise if it’s found at the margins. If your pathology report mentions pleomorphic or florid LCIS, expect a more active treatment plan than for the classic type.
The Upgrade Question
One concern after an LCIS diagnosis on a needle biopsy is the “upgrade rate,” meaning how often a follow-up surgical excision reveals actual cancer that the needle missed. For classic LCIS, this happens about 9% of the time. That’s high enough that many specialists recommend a surgical excision after LCIS is found on a core biopsy, even though the LCIS itself isn’t cancer. The goal is to make sure nothing more concerning is lurking nearby in tissue the needle didn’t sample.
Screening After an LCIS Diagnosis
Because LCIS raises your long-term breast cancer risk, screening becomes more frequent and thorough. Current guidelines from the National Comprehensive Cancer Network recommend:
- Clinical breast exams every 6 to 12 months
- Annual mammograms, preferably 3D (tomosynthesis), starting at the age of diagnosis but not before 30
- Annual breast MRI to consider starting at the time of diagnosis but not before age 25
The MRI catches cancers that mammograms miss, particularly in denser breast tissue. If you can’t have an MRI (due to claustrophobia, implanted devices, or other reasons), contrast-enhanced mammography or whole-breast ultrasound are alternatives.
Medication to Lower the Risk
Several medications can meaningfully cut the odds of developing invasive breast cancer after an LCIS diagnosis. These aren’t chemotherapy. They work by blocking or lowering the hormones that fuel most breast cancers.
Tamoxifen, the most studied option, reduces the risk of both invasive and non-invasive breast cancer by about 50% in women with LCIS. It works for both premenopausal and postmenopausal women. A lower-dose regimen (5 mg daily for three years, rather than the traditional 20 mg) showed a similar 50% risk reduction in an Italian study, with fewer side effects.
For postmenopausal women, there are additional choices. Raloxifene retains about 76% of tamoxifen’s effectiveness, translating to roughly a 38% reduction in breast cancer risk. Aromatase inhibitors offer another path: exemestane reduced annual breast cancer incidence by 65% in one trial, while anastrozole cut risk by 53%. Your age, menopausal status, and personal risk factors determine which option makes the most sense.
These medications do carry side effects (hot flashes, joint pain, and in some cases increased clotting risk), so the decision involves weighing your individual cancer risk against the drug’s downsides. Not everyone with LCIS chooses medication, and that’s a reasonable decision when paired with close surveillance.
What LCIS Means for Your Long-Term Outlook
The most important thing to understand is that LCIS raises your risk equally in both breasts, not just the one where it was found. Any future cancer that develops may be lobular or ductal, and it may appear in either breast. This is why LCIS is considered a general risk factor for breast cancer rather than a precursor lesion in one specific spot.
A 25% to 30% lifetime risk sounds high, and it is roughly double the average. But it also means there’s a 70% to 75% chance you won’t develop breast cancer at all. With enhanced screening catching cancers earlier and risk-reduction medications cutting the odds significantly, the practical outlook for someone with LCIS is far better than the name might suggest.